CN113544156A - 抗Claudin18.2抗体及其应用 - Google Patents
抗Claudin18.2抗体及其应用 Download PDFInfo
- Publication number
- CN113544156A CN113544156A CN202080019073.9A CN202080019073A CN113544156A CN 113544156 A CN113544156 A CN 113544156A CN 202080019073 A CN202080019073 A CN 202080019073A CN 113544156 A CN113544156 A CN 113544156A
- Authority
- CN
- China
- Prior art keywords
- variable region
- chain variable
- seq
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本公开涉及抗Claudin18.2抗体及其应用。具体地,本发明涉及一种抗Claudin18.2抗体;包含所述抗Claudin18.2抗体CDR的鼠源抗体、嵌合抗体、人源化抗体及其抗原结合片段,以及其作为药物的用途。特别地,本公开涉及一种抗Claudin18.2抗体在制备用于治疗Claudin18.2阳性疾病或病症的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (17)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211305192.8A CN116063516A (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910257853 | 2019-04-01 | ||
CN2019102578536 | 2019-04-01 | ||
PCT/CN2020/082369 WO2020200196A1 (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211305192.8A Division CN116063516A (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113544156A true CN113544156A (zh) | 2021-10-22 |
CN113544156B CN113544156B (zh) | 2022-11-22 |
Family
ID=72664673
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211305192.8A Pending CN116063516A (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
CN202080019073.9A Active CN113544156B (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211305192.8A Pending CN116063516A (zh) | 2019-04-01 | 2020-03-31 | 抗Claudin18.2抗体及其应用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220185881A1 (zh) |
EP (1) | EP3950716A4 (zh) |
JP (1) | JP2022528061A (zh) |
KR (1) | KR20210148216A (zh) |
CN (2) | CN116063516A (zh) |
AU (1) | AU2020250601A1 (zh) |
BR (1) | BR112021019135A2 (zh) |
CA (1) | CA3134411A1 (zh) |
MX (1) | MX2021011489A (zh) |
WO (1) | WO2020200196A1 (zh) |
ZA (1) | ZA202106880B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115947855A (zh) * | 2022-05-20 | 2023-04-11 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113226367A (zh) | 2018-04-06 | 2021-08-06 | Atyr 医药公司 | 包括抗nrp2抗体的组合物和方法 |
JP2022519118A (ja) | 2019-02-01 | 2022-03-18 | ノヴァロック バイオセラピューティクス, リミテッド | 抗クローディン18抗体及びそれらの使用の方法 |
CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
BR112022011032A2 (pt) * | 2019-12-12 | 2022-08-16 | Jiangsu Hengrui Medicine Co | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo |
CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
CN114634566B (zh) * | 2020-12-16 | 2023-09-19 | 广州百暨基因科技有限公司 | 一种抗Claudin18_2的抗原结合片段、抗体及其应用 |
WO2022136642A1 (en) | 2020-12-23 | 2022-06-30 | Sotio Biotech A.S. | Tumor-specific claudin 18.2 antibody-drug conjugates |
CN114685682B (zh) * | 2020-12-31 | 2023-11-10 | 上海莱馥医疗科技有限公司 | 一种靶向表达cldn 18.2的细胞的嵌合抗原受体 |
EP4304658A1 (en) * | 2021-03-08 | 2024-01-17 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody-immune agonist conjugate and applications thereof |
CN113416260B (zh) * | 2021-04-14 | 2022-02-01 | 南京凯地医疗技术有限公司 | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 |
CN118355033A (zh) * | 2021-10-27 | 2024-07-16 | Atyr 医药公司 | 包含抗NRP2a抗体的组合物和方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104321345A (zh) * | 2012-05-09 | 2015-01-28 | 加尼梅德药物公司 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN104379166A (zh) * | 2012-05-23 | 2015-02-25 | 加尼梅德药物公司 | 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗 |
WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2061814T1 (sl) | 2006-10-27 | 2012-09-28 | Genentech Inc | Protitelesa in imunokonjugati in njihove uporabe |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
CN106794258B (zh) | 2015-02-15 | 2019-07-12 | 江苏恒瑞医药股份有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
BR112022011032A2 (pt) * | 2019-12-12 | 2022-08-16 | Jiangsu Hengrui Medicine Co | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo |
-
2020
- 2020-03-31 CN CN202211305192.8A patent/CN116063516A/zh active Pending
- 2020-03-31 MX MX2021011489A patent/MX2021011489A/es unknown
- 2020-03-31 KR KR1020217034462A patent/KR20210148216A/ko unknown
- 2020-03-31 US US17/442,939 patent/US20220185881A1/en active Pending
- 2020-03-31 WO PCT/CN2020/082369 patent/WO2020200196A1/zh unknown
- 2020-03-31 AU AU2020250601A patent/AU2020250601A1/en active Pending
- 2020-03-31 JP JP2021557129A patent/JP2022528061A/ja active Pending
- 2020-03-31 EP EP20782022.6A patent/EP3950716A4/en active Pending
- 2020-03-31 CN CN202080019073.9A patent/CN113544156B/zh active Active
- 2020-03-31 CA CA3134411A patent/CA3134411A1/en active Pending
- 2020-03-31 BR BR112021019135A patent/BR112021019135A2/pt unknown
-
2021
- 2021-09-17 ZA ZA2021/06880A patent/ZA202106880B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104321345A (zh) * | 2012-05-09 | 2015-01-28 | 加尼梅德药物公司 | 用于癌症诊断的针对密蛋白18.2的抗体 |
CN104379166A (zh) * | 2012-05-23 | 2015-02-25 | 加尼梅德药物公司 | 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗 |
WO2018006882A1 (zh) * | 2016-07-08 | 2018-01-11 | 科济生物医药(上海)有限公司 | 抗密蛋白18a2的抗体及其应用 |
WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
Non-Patent Citations (2)
Title |
---|
BRYCE NELSON等: "Structure-Guided Combinatorial Engineering Facilitates Affinity and Specificity Optimization of Anti-CD81 Antibodies", 《JOURNAL OF MOLECULAR BIOLOGY》 * |
徐良额等: "CLDN18.2 蛋白在恶性肿瘤治疗中的研究进展", 《中国肿瘤临床》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115947855A (zh) * | 2022-05-20 | 2023-04-11 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
CN115947855B (zh) * | 2022-05-20 | 2023-10-27 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
Also Published As
Publication number | Publication date |
---|---|
CN116063516A (zh) | 2023-05-05 |
TW202102546A (zh) | 2021-01-16 |
BR112021019135A2 (pt) | 2021-11-30 |
CN113544156B (zh) | 2022-11-22 |
EP3950716A1 (en) | 2022-02-09 |
WO2020200196A1 (zh) | 2020-10-08 |
US20220185881A1 (en) | 2022-06-16 |
AU2020250601A1 (en) | 2021-11-18 |
ZA202106880B (en) | 2023-02-22 |
CA3134411A1 (en) | 2020-10-08 |
EP3950716A4 (en) | 2022-11-09 |
MX2021011489A (es) | 2021-10-22 |
KR20210148216A (ko) | 2021-12-07 |
JP2022528061A (ja) | 2022-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113544156B (zh) | 抗Claudin18.2抗体及其应用 | |
JP7317272B2 (ja) | Tigit抗体、その抗原結合断片及びその医療用途 本願は、2019年9月29日に出願された出願番号cn201710908565.3に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 | |
CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
TW201909926A (zh) | B7h3抗體-藥物偶聯物及其醫藥用途 | |
US11359021B2 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
CN113906053B (zh) | 抗cea抗体及其应用 | |
TW202017945A (zh) | 抗cd73抗體、其抗原結合片段及應用 | |
WO2021098822A1 (zh) | 一种双特异性抗体 | |
WO2021190441A1 (zh) | Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用 | |
KR101259239B1 (ko) | PcrV에 대한 항체 | |
TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
CN110606892B (zh) | 一种高亲和力高生物活性的lag-3抗体及其应用 | |
CN113597432B (zh) | 抗EpCAM抗体及其应用 | |
TWI848090B (zh) | 密蛋白抗體及其應用 | |
RU2822550C2 (ru) | Антитело против клаудина 18.2 и его применение | |
RU2822550C9 (ru) | Антитело против клаудина 18.2 и его применение | |
CN118496364A (zh) | uPARAP特异性结合蛋白及其制备方法和应用 | |
WO2022078424A1 (zh) | 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40060501 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |